

South Tyneside and Sunderland Area Prescribing Committee Recommendation Summary

Summary of recommendations made regarding new product requests considered at a meeting of the Committee on **Wednesday April 3rd 2019**

Classification of products:

R = 'RED' drugs for hospital use only

A = 'AMBER' drugs suitable for use under Shared Care arrangements

G+ = 'GREEN PLUS' – Drugs normally recommended or initiated by hospital specialist, but can be safely maintained in primary care with very little or no monitoring required. Any information is often appropriate to support safe prescribing

G = 'GREEN' – Drugs where initiation by GPs is appropriate

U Unlicensed medicine

NICE Approved by NICE as a technology appraisal

Product	Recommendation			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				Recommendation:
2) New Requests				
Nebulised Colistimethate for Bronchiectasis	✓ G+			Subject to GP information leaflet & patient leaflet– must include specific brand. Once the information leaflet is produced it needs final review by the APC for final sign off. Off label indication.
Budesonide (Jorveza®) 1mg orodispersible tablets for Eosinophilic Oesophagitis	✓ G+			AGREED initial course is prescribed in full by secondary care and then moved to primary care. Green plus information leaflet required. Once produced, information leaflet will require final review by the APC to approve the leaflet
3) New formulations / extensions to use or RAG status				
None				
4) Products considered by NICE				
TA555 : Regorafenib for previously treated advanced hepatocellular carcinoma				The formulary will reflect the NICE position
TA556 : Darvadstrocel for treating complex perianal fistulas in Crohn's disease				The formulary will reflect the NICE position
TA557 : Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small cell lung cancer				The formulary will reflect the NICE position

Product	Recommendation			Comments/notes
	Approved	Refused	Deferred	
TA558 : Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease				The formulary will reflect the NICE position
TA559 : Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies.				The formulary will reflect the NICE position
TA560 : Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)				The formulary will reflect the NICE position
TA561 : Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia				The formulary will reflect the NICE position
TA562 : Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma				The formulary will reflect the NICE position
TA563 : Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer				The formulary will reflect the NICE position
TA564 : Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)				The formulary will reflect the NICE position
TA572 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes				The formulary will reflect the NICE position Fast Track Appraisal. Requires implementation by 26/4/19
5) Northern (NHS) Treatment Advisory Group (N-TAG)				
i-Port Advance® for use in children and adults with Type 1 diabetes				The formulary will reflect the N – TAG position
6) Regional Medicines Optimisation Committee (RMOC)				
None				
7) Appeals against earlier decisions by the APC				
None				
8) Guidelines approved.				
Opioid Prescribing for Chronic Pain: Resource Pack	✓			Additional items to be added as discussed at meeting

Product	Recommendation			Comments/notes
	Approved	Refused	Deferred	
Opioid prescribing position statement Sunderland CCG	✓			For implementation by South Tyneside CCG also
Freestyle Libre NTAG statement	✓			Discussed changes to NHSE guidance at meeting. Agreed to follow regional approach. NTAG position statement circulated after meeting
9) Miscellaneous recommendations				
None				